• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Good Cholesterol Compound Inhibits Growth of Lung Tumors

A compound that mimics the main protein in high-density lipoprotein cholesterol — HDL, or “good” cholesterol — significantly reduced the number of tumors in the lungs of mice, a team of UCLA researchers reports. The findings help explain the connection between HDL cholesterol and reduced cancer risk and suggest that a similar compound may be an effective therapy in humans.

Previous research, both in lab animals and humans, had suggested that higher HDL cholesterol levels were linked to reduced cancer risk. The team’s earlier work had found that small peptide “mimetics,” or mimics, of an HDL protein reduced tumor growth in mice, but it was not totally clear which immune and genetic mechanisms were responsible for the connection. The new study, says Srinivasa Reddy, PhD, professor in the Departments of Medicine and Molecular & Medical Pharmacology, set out to determine if and how the compound, called Tg6F, might alter the immune system both in the intestine and in a distant organ, in this case, the lung.

Good Cholesterol Compound Inhibits Growth of Lung Tumors

Representative pictures of lungs with tumors from mice fed normal diet (Chow) or normal diet that was supplemented with transgenic tomato extract containing Tg6F peptide (Chow+Tg6F). Image: Courtesy of Dr. Arnab Chattopadhyay

The team used a mouse model of lung cancer, injecting cancer cells into the tail veins of mice, explains Arnab Chattopadhyay, PhD, assistant project scientist in the UCLA Department of Medicine. The cancerous cells migrate to the lungs, where they grow into tumors. One group of mice was given Tg6F orally, starting the day after they were injected with cancer cells, along with their regular mouse food; another group of mice received an inactive version of the compound. After four weeks of treatment, the number of tumor nodules was significantly lower in the lungs of Tg6F-fed mice — on average 75 percent lower than controls, Dr. Chattopadhyay says.

The team also looked at how the compound was exerting its anticancer effects and found that Tg6F altered lipid metabolism in the small intestine, which in turn altered gene expression and the type of immune cells present in both the intestine and the lung. In particular, the Tg6F supplements increased the expression of genes in a pathway that boosts white blood cells patrolling for cancer and decreased gene expression in a pathway that facilitates cancer growth.

The findings, Dr. Reddy says, illuminate the mechanisms by which “good” cholesterol may reduce cancer risk and underscore how important the small intestine is in exerting immune effects in distant organs. These results suggest that oral compounds may have therapeutic value for treating lung cancer in humans. The team next plans to study if Tg6F also inhibits tumor growth in other organs of the body.

“Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer,” Scientific Reports, June 13, 2018.

 


Previous
Men at Risk for Breast Cancer but Often Forego Genetic Tests
Next
Public Mental Health Care for Older Californians Lags as Need Grows


YOU ARE VIEWING

Fall 2018

Fall 2018
Printable PDF
IN THIS ISSUE
  • A Decade of Care and Discovery
  • After Two Years in Darkness and Pain, a Young Woman Sees Again
  • How Colon Cancer Mutates to Escape Immune System
  • Men at Risk for Breast Cancer but Often Forego Genetic Tests
  • Good Cholesterol Compound Inhibits Growth of Lung Tumors
  • Public Mental Health Care for Older Californians Lags as Need Grows
  • Gel Material May Help to Regrow Brain Tissue Following Stroke
  • Present at the Creation
  • Reach for the Stars
  • Dr. Plath’s Pluripotent-ial
  • The Pluripotent-ialist: Expanded Interview with Dr. Kathrin Plath
  • How Immunotherapy Became the Next Big Thing
  • The Prize
  • Invisible Pain
  • Virtual Traveler
  • Awards & Honors
  • Return of the Class of ’98
  • Focusing on Whole Health at The Wonder of Women Summit
  • UCLA Medical Center Boards Pass the Gavel
  • Taste for a Cure Raises Money for Cancer Research
  • Using Metabolism to Drive Breakthroughs in Cancer Research
  • Giving Back to Change Lives
  • UCLA Semel Institute Introduces the New Max Gray Fellows in Mood Disorders
  • UCLA Takes on Depression
  • Music and Philanthropy Advance Autism Care
  • Building Connections between Art and Neuroscience at Hammer Museum
  • Tour de Pier Continues to Exceed its Fundraising Goals
  • Bringing Awareness to Food Allergies
  • A Breath of Lung Health
  • Altering the Course of Cardiovascular Research at UCLA
  • Gifts
  • In Memoriam
  • A Blessed Man
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth